龚军

5.4k citations

160 papers · 4.1k · 2 hit papers · h-index 30

Impact in

Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Oncology 77
- Cancer Immunotherapy and Biomarkers 25
- Pancreatic and Hepatic Oncology Research 24
- Colorectal Cancer Treatments and Studies 15
Pulmonary and Respiratory Medicine 36
- Gastric Cancer Management and Outcomes 9
- Prostate Cancer Treatment and Research 7
- Renal cell carcinoma treatment 7

Co-authors: Ravi Salgia (7 shared papers)Alex Chehrazi‐Raffle (3 shared papers)Andrew Eugene Hendifar (60 shared papers)Marwan Fakih (17 shared papers)May Thet Cho (28 shared papers)Monica M Mita (5 shared papers)Richard Tuli (12 shared papers)Sumanta Kumar Pal (7 shared papers)
Journals: Cancers (12 papers)Journal of the National Comprehensive Cancer Network (7 papers)JCO Precision Oncology (5 papers)Oncotarget (5 papers)Frontiers in Oncology (4 papers)
Partner nations: United States China Germany

In The Last Decade

龚军

151 papers receiving 4k citations

龚军's Hit Papers

align trajectories log scale

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study 2023 · 183 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2023 The Lancet Oncology
2018 Journal for ImmunoTherapy of Cancer

Peers

Countries citing papers authored by 龚军

Since Specialization

Citations

This map shows the geographic impact of 龚军's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by 龚军 with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites 龚军 more than expected).

Fields of papers citing papers by 龚军

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by 龚军. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by 龚军. The network helps show where 龚军 may publish in the future.

Co-authors

The 25 scholars most cited alongside 龚军, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with 龚军 Line = papers co-authored together 龚军 links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 160 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations Journal for ImmunoTherapy of Cancer ·龚军, Alex Chehrazi‐Raffle, Srikanth Reddi, Ravi Salgia Hit paper breakdown →	2018	1065
2	Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring aPOLEMutation Journal of the National Comprehensive Cancer Network ·龚军, Chongkai Wang, Peter P. Lee, Peiguo G. Chu, Marwan Fakih	2017	188
3	Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study The Lancet Oncology ·John H. Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew Scott Paulson Hit paper breakdown →	2023	183
4	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination Journal for ImmunoTherapy of Cancer ·龚军, Thang Q. Le, Erminia Massarelli, Andrew Eugene Hendifar, Richard Tuli	2018	165
5	Metastasis in renal cell carcinoma: Biology and implications for therapy Asian journal of urology ·龚军, Manuel Caitano Maia, Nazlı Dizman, Ameish Govindarajan, Sumanta Kumar Pal	2016	123
6	Recent advances in the management of hepatocellular carcinoma Clinical and Molecular Hepatology ·K. Nathan Sankar, 龚军, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew Eugene Hendifar, Ekaterina K. Koltsova	2023	97
7	The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies Clinical and Translational Medicine ·龚军, Alex Chehrazi‐Raffle, Veronica Placencio-Hickok, Michelle Guan, Andrew Eugene Hendifar, Ravi Salgia	2019	87
8	Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life Cancers ·Daneng Li, Sabrina Sedano, Rebecca Sue Allen, 龚军, May Thet Cho, Sunil Sharma	2019	75
9	Activated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells Frontiers in Oncology ·龚军, Monica M Mita	2014	68
10	Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy Journal of Gastrointestinal Oncology ·Chongkai Wang, 龚军, Travis Yiwey Tu, Peter P. Lee, Marwan Fakih	2018	59
11	RAS and BRAF in metastatic colorectal cancer management Journal of Gastrointestinal Oncology ·龚军, May Thet Cho, Marwan Fakih	2016	58
12	COVID-19 and androgen-targeted therapy for prostate cancer patients Endocrine Related Cancer ·Neil A. Bhowmick, Jillian R. Oft, Tanya Barauskas Dorff, Sumanta Kumar Pal, Neeraj Agarwal, Robert A. Figlin, Edwin M. Posadas, Stephen J. Freedland	2020	58
13	Advances in Pancreatic Ductal Adenocarcinoma Treatment Cancers ·Eric M. Anderson, Shant Thomassian, 龚军, Andrew Eugene Hendifar, Arsen Osipov	2021	58
14	Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis Journal of Ovarian Research ·龚军, Hui Jiang, Chang Shu, Mei-Qin Hu, Yan Huang, Qin Liu +1 other	2019	54
15	The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development Targeted Oncology ·龚军, Gauri Kelekar, James Shen, John Shen, Monica M Mita +1 other	2016	52
16	HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma Oncology Reports ·Zhihao Wang, Pengchao Hu, Ying Wang, 龚军, Shaoxing Sun, Conghua Xie +1 other	2016	51
17	Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas Drug Design Development and Therapy ·龚军, Jessica E. Yan, Charles A. Forscher, Andrew Hendifar	2018	51
18	Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy Gastroenterology ·Alex B. Blair, John Davelaar, Keyu Li, Nan Niu, Junke Wang, Yingkuan Shao, Vanessa Funes, Pan Li	2022	50
19	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience Oncotarget ·龚军, May Thet Cho, Marvin Sy, Ravi Salgia, Marwan Fakih	2017	49
20	Diabetes, pancreatic cancer, and metformin therapy Frontiers in Physiology ·龚军, Lori Robbins, Aurelia Lugea, Richard T. Waldron, Christie Y. Jeon, Stephen Jacob Pandol	2014	48

About 龚军

龚军 is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hepatology, Cancer Research and Pathology and Forensic Medicine, having authored 160 papers that have together received 4.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (25 papers), Pancreatic and Hepatic Oncology Research (24 papers), Colorectal Cancer Treatments and Studies (15 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers), Gastric Cancer Management and Outcomes (9 papers), Prostate Cancer Treatment and Research (7 papers), Renal cell carcinoma treatment (7 papers) and Genetic factors in colorectal cancer (6 papers). The work is most often cited by research in Oncology (2k citations), Hepatology (220 citations), Cancer Research (290 citations), Pulmonary and Respiratory Medicine (556 citations) and Immunology (225 citations) 龚军 has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Ravi Salgia, Alex Chehrazi‐Raffle, Andrew Eugene Hendifar, Marwan Fakih, May Thet Cho, Monica M Mita, Richard Tuli, Sumanta Kumar Pal, Chongkai Wang and Peter P. Lee. Their work appears in journals such as Cancers, Journal of the National Comprehensive Cancer Network, JCO Precision Oncology, Oncotarget and Frontiers in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

龚军